Mitochondrial DNA (mtDNA) as fluid biomarker in neurodegenerative disorders: A systematic review.

Eur J Neurol · 2025 · PMC11744304 · PMID 39831374

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Other authors found a similar decreasing trend for CSF mtDNA in iPD compared to HC, but the difference did not reach statistical significance [ 41 , 42 ].

also in 111,027 other papers

a decreasing trendno p-value reported

showed (i) a decreasing trend of mtDNA‐CN with an increasing number of APOE4 alleles carried by AD patients; (ii) increased mtDNA‐CN in AD patients treated with acetylcholinesterase inhibitors compared to drug‐naïve patients [ 65 ]. mtDNA heteroplasmy, damage and methylation The studies addressing mtDNA heteroplasmy in AD showed contrasting results.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.